[
  {
    "ts": "2026-02-13T09:32:17+00:00",
    "headline": "Analysis-China biotech licensing boom to hit record in 2026 as pipeline swells",
    "summary": "By Kane Wu and Andrew Silver HONG KONG/SHANGHAI, Feb 13 (Reuters) - Global drugmakers are stepping up their search for China‑developed experimental medicines as they cut costs ahead of patent",
    "url": "https://finance.yahoo.com/news/analysis-china-biotech-licensing-boom-092338804.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "c3513fec-0fd0-35e5-a4af-ce21f8298993",
      "content": {
        "id": "c3513fec-0fd0-35e5-a4af-ce21f8298993",
        "contentType": "STORY",
        "title": "Analysis-China biotech licensing boom to hit record in 2026 as pipeline swells",
        "description": "",
        "summary": "By Kane Wu and Andrew Silver HONG KONG/SHANGHAI, Feb 13 (Reuters) - Global drugmakers are stepping up their search for China‑developed experimental medicines as they cut costs ahead of patent",
        "pubDate": "2026-02-13T09:32:17Z",
        "displayTime": "2026-02-13T09:32:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/ac6bc36f2eeea0b87ca80119317f477d",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "A sign marks the Novartis Institutes for BioMedical Research facility in Cambridge, Massachusetts, U.S., June 16, 2021.   REUTERS/Brian Snyder",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wNkas3Ojb6L_Qs0iS1Bl0Q--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/ac6bc36f2eeea0b87ca80119317f477d.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/e9O53XCBrj9YyJo3Jm9Tzg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/ac6bc36f2eeea0b87ca80119317f477d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysis-china-biotech-licensing-boom-092338804.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysis-china-biotech-licensing-boom-092338804.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVS"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T13:00:36+00:00",
    "headline": "Merck stock upside: Why Deutsche Bank sees 26% growth despite Keytruda patent",
    "summary": "Investing.com -- Merck (NYSE: MRK) stock rose 2% Friday morning after Deutsche Bank analyst James Shin upgraded the pharmaceutical giant from Hold to Buy, setting a price target of $150.00, up from $115.00.",
    "url": "https://finance.yahoo.com/news/merck-stock-upside-why-deutsche-130036976.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "29c16f99-eae1-36a9-bb00-b03a1899100a",
      "content": {
        "id": "29c16f99-eae1-36a9-bb00-b03a1899100a",
        "contentType": "STORY",
        "title": "Merck stock upside: Why Deutsche Bank sees 26% growth despite Keytruda patent",
        "description": "",
        "summary": "Investing.com -- Merck (NYSE: MRK) stock rose 2% Friday morning after Deutsche Bank analyst James Shin upgraded the pharmaceutical giant from Hold to Buy, setting a price target of $150.00, up from $115.00.",
        "pubDate": "2026-02-13T13:00:36Z",
        "displayTime": "2026-02-13T13:00:36Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-stock-upside-why-deutsche-130036976.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-stock-upside-why-deutsche-130036976.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T13:59:27+00:00",
    "headline": "Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid January Consumer Price Inflation Report",
    "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively tr",
    "url": "https://finance.yahoo.com/news/exchange-traded-funds-equity-futures-135927712.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "2273320c-a247-3885-a796-0d8db0cffa22",
      "content": {
        "id": "2273320c-a247-3885-a796-0d8db0cffa22",
        "contentType": "STORY",
        "title": "Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid January Consumer Price Inflation Report",
        "description": "",
        "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively tr",
        "pubDate": "2026-02-13T13:59:27Z",
        "displayTime": "2026-02-13T13:59:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/exchange-traded-funds-equity-futures-135927712.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/exchange-traded-funds-equity-futures-135927712.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BTC-USD"
            },
            {
              "symbol": "QQQ"
            },
            {
              "symbol": "BITO"
            },
            {
              "symbol": "SPY"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "BKR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T13:49:35+00:00",
    "headline": "Stock Market Today: Dow Falls On Surprise CPI Inflation Report; DraftKings Plunges On Earnings (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index dropped Friday on a surprise CPI inflation report. DraftKings plunged on earnings.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-cpi-inflation-report-draftkings-dkng/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "b8c56085-66da-3c0e-b403-2b57226b99c8",
      "content": {
        "id": "b8c56085-66da-3c0e-b403-2b57226b99c8",
        "contentType": "STORY",
        "title": "Stock Market Today: Dow Falls On Surprise CPI Inflation Report; DraftKings Plunges On Earnings (Live Coverage)",
        "description": "",
        "summary": "Stock Market Today: The Dow Jones index dropped Friday on a surprise CPI inflation report. DraftKings plunged on earnings.",
        "pubDate": "2026-02-13T13:49:35Z",
        "displayTime": "2026-02-13T13:49:35Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/b8c56085-66da-3c0e-b403-2b57226b99c8/stock-market-today-dow-falls.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/55ca4252bd7c66820fc61ce444908e68",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RkIoP5aIoaWmMg1KUnpqdg--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/55ca4252bd7c66820fc61ce444908e68.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Wh39EUbEziJHgMn.DZRyfQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/55ca4252bd7c66820fc61ce444908e68.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-cpi-inflation-report-draftkings-dkng/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DKNG"
            },
            {
              "symbol": "BTC-USD"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "CL=F"
            },
            {
              "symbol": "^NDX"
            },
            {
              "symbol": "QQQ"
            },
            {
              "symbol": "SPY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "AMZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T15:35:00+00:00",
    "headline": "Did Eli Lilly Just Make a Deal for Its Next Blockbuster Drug?",
    "summary": "Eli Lilly announced an acquisition of an innovative new autoimmune drug.",
    "url": "https://www.fool.com/investing/2026/02/13/did-eli-lilly-just-make-deal-for-next-blockbuster/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "c55e5da2-da7d-38b1-8415-cbe8cd85f7e8",
      "content": {
        "id": "c55e5da2-da7d-38b1-8415-cbe8cd85f7e8",
        "contentType": "STORY",
        "title": "Did Eli Lilly Just Make a Deal for Its Next Blockbuster Drug?",
        "description": "",
        "summary": "Eli Lilly announced an acquisition of an innovative new autoimmune drug.",
        "pubDate": "2026-02-13T15:35:00Z",
        "displayTime": "2026-02-13T15:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/2241df701d3f5a06d4ac71597643f582",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Scientists in a medical lab.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zYWf2wls7.7UM_d9KTtedg--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/2241df701d3f5a06d4ac71597643f582.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3xIBXFCN6qGQmoUWeOxsBA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/2241df701d3f5a06d4ac71597643f582.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/13/did-eli-lilly-just-make-deal-for-next-blockbuster/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/did-eli-lilly-just-deal-153500397.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T14:57:33+00:00",
    "headline": "Merck & Co. (MRK) Announces FDA Approval of KEYTRUDA® and KEYTRUDA QLEX™ Plus Paclitaxel, With or Without Bevacizumab, to Treat Adults With PD-L1+",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best medical research stocks to buy according to hedge funds. Merck & Co., Inc. (NYSE:MRK) announced on February 11 the FDA approval of KEYTRUDA® and KEYTRUDA QLEX™ plus paclitaxel, with or without bevacizumab, for the treatment of adults with PD-L1+, as determined by an FDA-authorized test, […]",
    "url": "https://finance.yahoo.com/news/merck-co-mrk-announces-fda-145733330.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "a18eee65-0583-36aa-87ee-1f17b4a21192",
      "content": {
        "id": "a18eee65-0583-36aa-87ee-1f17b4a21192",
        "contentType": "STORY",
        "title": "Merck & Co. (MRK) Announces FDA Approval of KEYTRUDA® and KEYTRUDA QLEX™ Plus Paclitaxel, With or Without Bevacizumab, to Treat Adults With PD-L1+",
        "description": "",
        "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best medical research stocks to buy according to hedge funds. Merck & Co., Inc. (NYSE:MRK) announced on February 11 the FDA approval of KEYTRUDA® and KEYTRUDA QLEX™ plus paclitaxel, with or without bevacizumab, for the treatment of adults with PD-L1+, as determined by an FDA-authorized test, […]",
        "pubDate": "2026-02-13T14:57:33Z",
        "displayTime": "2026-02-13T14:57:33Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/3c1e6d485df373db04a8fd19fdaf6c3a",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Why Merck & Co (MRK) Continues to Rank Among the Most Profitable Dividend Stocks",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IzRhrl6IP..dz_8NtaA67g--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/3c1e6d485df373db04a8fd19fdaf6c3a.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/C.KM1e7Q4T5mCkqt60S1Yg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/3c1e6d485df373db04a8fd19fdaf6c3a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-co-mrk-announces-fda-145733330.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-co-mrk-announces-fda-145733330.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T14:36:00+00:00",
    "headline": "Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?",
    "summary": "Gilead Sciences posts strong 2025 HIV growth despite a $900M headwind, as Biktarvy and Descovy lead and new launch Yeztugo gains momentum.",
    "url": "https://finance.yahoo.com/news/gileads-hiv-portfolio-sustain-growth-143600503.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "ac87d707-61ed-3773-a205-93ac5c80ea41",
      "content": {
        "id": "ac87d707-61ed-3773-a205-93ac5c80ea41",
        "contentType": "STORY",
        "title": "Can Gilead's HIV Portfolio Sustain Its Growth Trend in 2026?",
        "description": "",
        "summary": "Gilead Sciences posts strong 2025 HIV growth despite a $900M headwind, as Biktarvy and Descovy lead and new launch Yeztugo gains momentum.",
        "pubDate": "2026-02-13T14:36:00Z",
        "displayTime": "2026-02-13T14:36:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tEjPL1xniTl4Yv5crLKiVw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3wQ5IrbXljgjZ16xqKRVcQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/79b7ecb3a59852f0816e6eb69c31b2fe.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gileads-hiv-portfolio-sustain-growth-143600503.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gileads-hiv-portfolio-sustain-growth-143600503.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "GLAXF"
            },
            {
              "symbol": "GSK"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T14:30:05+00:00",
    "headline": "Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?",
    "summary": "Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
    "url": "https://finance.yahoo.com/news/merck-mrk-buy-wall-street-143005259.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "e6eff380-3ecf-3c7b-9960-d1f31fa90308",
      "content": {
        "id": "e6eff380-3ecf-3c7b-9960-d1f31fa90308",
        "contentType": "STORY",
        "title": "Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?",
        "description": "",
        "summary": "Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?",
        "pubDate": "2026-02-13T14:30:05Z",
        "displayTime": "2026-02-13T14:30:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619",
          "originalWidth": 900,
          "originalHeight": 506,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WMc9TPUzGnRwQQgeGPg3VQ--~B/aD01MDY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619.cf.webp",
              "width": 900,
              "height": 506,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kbEpsaBWvOchoGFZ2uOESQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3d7c5b2146ac04ffd51752e17ff2a619.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-buy-wall-street-143005259.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-buy-wall-street-143005259.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T14:00:05+00:00",
    "headline": "Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-attracting-140005018.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "33c0beba-b9ea-3250-927b-7ea639d37eab",
      "content": {
        "id": "33c0beba-b9ea-3250-927b-7ea639d37eab",
        "contentType": "STORY",
        "title": "Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know",
        "description": "",
        "summary": "Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.",
        "pubDate": "2026-02-13T14:00:05Z",
        "displayTime": "2026-02-13T14:00:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/090f58c1efbe3555b861102525e50b39",
          "originalWidth": 900,
          "originalHeight": 601,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yNgUIaj6nVgElt8k_HeWJg--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/090f58c1efbe3555b861102525e50b39.cf.webp",
              "width": 900,
              "height": 601,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pjdR96PEF4KSKZclyxD5FQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/090f58c1efbe3555b861102525e50b39.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-attracting-140005018.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-co-inc-mrk-attracting-140005018.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T15:49:00+00:00",
    "headline": "MRK Up More Than 7% on Improved Long-Term Prospects: Still a Sell?",
    "summary": "Merck stock has risen more than 7% in a month on a stronger long-term outlook, but 2026 headwinds, Keytruda patent risk and Gardasil slump keep it a Sell.",
    "url": "https://finance.yahoo.com/news/mrk-more-7-improved-long-154900389.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "64706c27-0a1d-3d82-96f7-a6a85aca8638",
      "content": {
        "id": "64706c27-0a1d-3d82-96f7-a6a85aca8638",
        "contentType": "STORY",
        "title": "MRK Up More Than 7% on Improved Long-Term Prospects: Still a Sell?",
        "description": "",
        "summary": "Merck stock has risen more than 7% in a month on a stronger long-term outlook, but 2026 headwinds, Keytruda patent risk and Gardasil slump keep it a Sell.",
        "pubDate": "2026-02-13T15:49:00Z",
        "displayTime": "2026-02-13T15:49:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A9LQHlDmqgPJbKsotfjd8w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o5.ym16dSp_UIlCHMRMZUw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/mrk-more-7-improved-long-154900389.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/mrk-more-7-improved-long-154900389.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]